AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Phase Ib/II Clinical Study of Adebrelimab Combined with Decitabine, Nab-Paclitaxel, and Gemcitabine as First-Line (IL) Treatment for Metastatic Pancreatic Cancer (mPC) (ESMO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Oncology • Pancreatic Cancer • Solid Tumor

Famitinib Plus Adebrelimab for Advanced Thyroid Cancer After Failed Frontline Treatment: A Single-Arm, Open-Label Phase II Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Primary Analysis of Efficacy and Safety of Adebrelimab Combined with Famitinib and Chemotherapy as First-line Therapy for ES-SCLC: A multicenter, single-arm, phase II study (ESMO 2025) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Prospective Study of Neoadjuvant Adebrelimab Combined with Chemotherapy for Limited-Stage Small-Cell Lung Cancer (NIUS) (ESMO 2025) - No abstract available

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

RAPID trial (NCT06251492): Radiation and Adebrelimab in Metastatic Castration Resistant Prostate Cancer with Imaging-Measurable Disease (ESMO 2025) - P2 | No abstract available

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Neoadjuvant adebrelimab plus chemotherapy for locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, phase II trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Adebrelimab Plus Apatinib in Advanced Esophageal Squamous Cell Carcinoma Following Immune Checkpoint Inhibitors: Preliminary Results from Cohort 3 of CAP 02 Study (ESMO 2025) - No abstract available

Checkpoint inhibition • Metastases • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

First-line Adebrelimab Plus Anti-angiogenic Therapy in PD-L1 ≥50% NSCLC With Brain Metastases: Updated Results From the BRAIN-AF01 Study (ESMO 2025) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Neoadjuvant adebrelimab plus chemotherapy for locally advanced cervical cancer: a prospective, single-arm, phase II trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor

Adebrelimab plus Apatinib and Etoposide in the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study (ESMO 2025) - No abstract available

P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

SHR-A1921, a novel trophoblast cell-surface antigen 2 targeted antibody-drug conjugate, with or without adebrelimab in advanced triple-negative breast cancer (TNBC): data from two open-label, multicenter clinical trials (ESMO 2025) - No abstract available

Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

SHR-A1811 combined with Adebrelimab in HR-/HR-low, HER2-low metastatic breast cancer: Preliminary results from an open-label, single-arm, phase II Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Nanoliposomal Irinotecan with Oxaliplatin, Fluorouracil and Leucovorin in combined with Adebrelimab in Advanced Biliary Tract Cancer (NIOFA-01): A Phase 2 Clinical Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - P2 | N=716 | Recruiting | Sponsor: Fudan University | Trial completion date: Sep 2025 ➔ Sep 2028 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXC1 • HER-2 • PGR

Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis. (PubMed, Front Pharmacol) - "Immune checkpoint inhibitors (ICIs) combined with etoposide-platinum are recommended as the standard first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)...The drug combination patterns included ipilimumab, durvalumab, adebrelimab, atezolizumab, socazolimab, pembrolizumab, serplulimab, tislelizumab, toripalimab, durvalumab + tremelimumab, tiragolumab + atezolizumab, benmelstobart + anlotinib, bevacizumab + atezolizumab, anlotinib, bevacizumab in combination with chemotherapy...The toxicity of ICI + Antiangio + Chemo was acceptable but needed careful attention. These findings clarified the roles of ICIs and antiangiogenic agent-based treatment strategies in this population."

Journal • Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Harbin Medical University | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P3 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (clinicaltrials.gov) - P3 | N=400 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P3 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma (IASLC-WCLC 2025) - "Given the unmet clinical need for this rare malignancy, we conducted this study to evaluate the efficacy and safety of adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy for unresectable locally advanced thymic carcinoma. Conclusions : In patients with unresectable locally advanced thymic carcinoma, neoadjuvant adebrelimab combined with chemotherapy demonstrated promising efficacy and an acceptable safety profile. The trial is still ongoing to complete accrual in stage II."

Clinical • Metastases • Leukopenia • Neutropenia • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Adebrelimab Beyond Progression Plus Chemotherapy or Targeted Therapy as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer (IASLC-WCLC 2025) - P3 | "Introduction : The phase III IMfirst study (EudraCT: 2019-002784-10) showed that compared with no follow-up therapy and other treatments, atezolizumab beyond progression tends to prolong overall survival. Twenty-four-point-four percent of patients in the ASTRUM-005 trial continued to receive serplulimab after disease progression, which may be one of the key factors contributing to a lower overall survival hazard ratio (HR) of non-head-to-head comparison to the IMpower133, CASPIAN, and CAPSTONE-1 trials (HR 0.62 vs 0.76, 0.71, 0.73, respectively)...The secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Additional indicators include the relationship between T-cell subpopulation typing and number and therapeutic efficacy and the relationship between nutritional indicators and therapeutic effectiveness."

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer (clinicaltrials.gov) - P2 | N=37 | Recruiting | Sponsor: Yongjun Chen

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor